These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29687317)

  • 61. Ivabradine.
    Komajda M
    Handb Exp Pharmacol; 2017; 243():167-175. PubMed ID: 27752846
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease.
    Rimoldi SF; Messerli FH; Cerny D; Gloekler S; Traupe T; Laurent S; Seiler C
    Hypertension; 2016 Jun; 67(6):1205-10. PubMed ID: 27091900
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Heart rate predicts mortality in patients with heart failure and preserved systolic function.
    Kapoor JR; Heidenreich PA
    J Card Fail; 2010 Oct; 16(10):806-11. PubMed ID: 20932462
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
    Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
    Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Heart rate and heart failure: the role of ivabradine therapy.
    Reil JC; Böhm M
    Curr Opin Cardiol; 2013 May; 28(3):326-31. PubMed ID: 23549235
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Foundations of Pharmacotherapy for Heart Failure With Reduced Ejection Fraction: Evidence Meets Practice, Part I.
    Paul S; Page RL
    J Cardiovasc Nurs; 2016; 31(2):101-13. PubMed ID: 26296245
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [The efficacy of ivabradine in chronic heart failure (review)].
    Isakadze A; Makharadze T; Gvishiani M
    Georgian Med News; 2015 Apr; (241):44-9. PubMed ID: 25953938
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study.
    Takada T; Sakata Y; Miyata S; Takahashi J; Nochioka K; Miura M; Tadaki S; Shimokawa H;
    Eur J Heart Fail; 2014 Mar; 16(3):309-16. PubMed ID: 24464774
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball.
    Tschöpe C; Van Linthout S; Kherad B
    Curr Cardiol Rep; 2017 Aug; 19(8):70. PubMed ID: 28656481
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of Ivabradine on Inflammatory Markers in Chronic Heart Failure.
    Rohm I; Kretzschmar D; Pistulli R; Franz M; Schulze PC; Stumpf C; Yilmaz A
    J Immunol Res; 2016; 2016():6949320. PubMed ID: 27822484
    [No Abstract]   [Full Text] [Related]  

  • 71. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L
    Eur J Heart Fail; 2010 Jan; 12(1):75-81. PubMed ID: 19892778
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Ivabradine in coronary heart disease: experimental and clinical pharmacology].
    Pathak A; Berdeaux A; Mulder P; Thuillez C
    Therapie; 2010; 65(5):483-9. PubMed ID: 21144484
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
    Borer JS; Deedwania PC; Kim JB; Böhm M
    Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
    [TBL] [Abstract][Full Text] [Related]  

  • 74. β-Blockade in Heart Failure With Reduced Ejection Fraction: Does Heart Rate Control Influence Readmissions?
    Owens RE; Twilla JD; Self TH; Alshaya AI; Metra CJ; Cummings C; Oliphant CS
    J Pharm Pract; 2018 Feb; 31(1):40-45. PubMed ID: 28737066
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome.
    Singh S; Beadle R; Cameron D; Rudd A; Bruce M; Jagpal B; Schwarz K; Brindley G; Mckiddie F; Lang C; Dawson D; Frenneaux M
    Future Cardiol; 2014 Nov; 10(6):693-8. PubMed ID: 25495811
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade.
    Becher PM; Lindner D; Miteva K; Savvatis K; Zietsch C; Schmack B; Van Linthout S; Westermann D; Schultheiss HP; Tschöpe C
    Hypertension; 2012 May; 59(5):949-57. PubMed ID: 22493071
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of heart rate as a marker and mediator of poor outcome for patients with heart failure.
    Kapoor JR; Heidenreich PA
    Curr Heart Fail Rep; 2012 Jun; 9(2):133-8. PubMed ID: 22351045
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Heart failure with preserved left ventricular ejection fraction in patients with acute myocardial infarction.
    Antonelli L; Katz M; Bacal F; Makdisse MR; Correa AG; Pereira C; Franken M; Fava AN; Serrano Junior CV; Pesaro AE
    Arq Bras Cardiol; 2015 Aug; 105(2):145-50. PubMed ID: 26039659
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Beta-adrenoceptor blockers in chronic heart failure--a review.
    Krum H
    Br J Clin Pharmacol; 1997 Aug; 44(2):111-8. PubMed ID: 9278193
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ivabradine and outcomes in chronic heart failure.
    Gupta A; Sharma YP
    Lancet; 2010 Dec; 376(9758):2069; author reply 2069-70. PubMed ID: 21168044
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.